Caliway Biopharmaceuticals Co. L
6919
Classement en actions
#4344
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
Prix de l'action
$2.29
Capitalisation boursière
$3.56B
Changement (1 jour)
-2.50%
Changement (1 an)
-57.22%
Pays
TW
Échange Caliway Biopharmaceuticals Co. L (6919)
Catégorie
Healthcare
EPS pour Caliway Biopharmaceuticals Co. L (6919)
EPS au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Caliway Biopharmaceuticals Co. L, l’EPS actuel de la société (TTM) est de 0. À la fin de 2026, la société avait un EPS de 0 égal à celui de 2026, qui était de 0.
Historique de l'EPS de Caliway Biopharmaceuticals Co. L de 2026 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| Pas assez de données pour les dates fournies. | ||
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| $27.74 | - |
NL
|
|
| - | - |
CH
|
